GlassScriptPhysician profile
Juan Claros-Sorto
NPI 1043571664
$3,022.22
in general payments reported to CMS, 2019-2025
12 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2021: $19.09 · 2022: $331 · 2023: $965 · 2024: $449 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,795.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $1,253.32 | 2022-2025 | Avance Nerve Graft, Axoguard Nerve Cap, Axoguard Ha+ Nerve Protector |
| Medtronic USA, INC. | $876.58 | 2019 | |
| Daiichi Sankyo INC. | $270.36 | 2022-2025 | Enhertu |
| Endomagnetics LTD | $176.55 | 2023 | Magtrace, Magseed |
| Merit Medical Systems INC | $117.91 | 2025 | Savi Scout |
| Merck Sharp & Dohme LLC | $99.44 | 2023-2025 | Keytruda, Lynparza |
| Seagen INC. | $69.99 | 2022-2023 | Tukysa |
| Myriad Genetic Laboratories, INC. | $51.42 | 2021-2023 | Myrisk |
| Elucent Medical | $32.47 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $31.37 | 2022-2025 | Enhertu |
| Lilly USA, LLC | $23.09 | 2023 | Retevmo |
| Tempus Ai, INC | $19.72 | 2024 | Xt Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Claros-Sorto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.